When was TEMPEST THERAPEUTICS founded?

TEMPEST THERAPEUTICS was founded in 2011 and raised its 1st funding round within a year of its incorporation.

Where is TEMPEST THERAPEUTICS located?

TEMPEST THERAPEUTICS is headquartered in San Francisco, United States.

How many employees does TEMPEST THERAPEUTICS have?

As of Apr 30, 2026, the latest employee count at TEMPEST THERAPEUTICS is 14.

Is TEMPEST THERAPEUTICS a funded company?

TEMPEST THERAPEUTICS is a funded company, having raised a total of $88.2M across 5 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Nov 23, 2011.

When was the latest funding round of TEMPEST THERAPEUTICS?

TEMPEST THERAPEUTICS's latest funding was a $***** Post IPO round on Mar 23, 2026, with participation from 0 investor.

Where does TEMPEST THERAPEUTICS rank among its competitors?

TEMPEST THERAPEUTICS ranks 170th amongst 3220 active competitors, of which 1104 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was TEMPEST THERAPEUTICS, which secured $6M in Mar, 2026.

Who are the top competitors of TEMPEST THERAPEUTICS?

TEMPEST THERAPEUTICS's top competitors include Jazz Pharmaceuticals, Moderna and Sana Biotechnology. Among them, TEMPEST THERAPEUTICS secured the most recent funding round in March, 2026.

TEMPEST THERAPEUTICS - 2026 Company Profile, Funding, Competitors & Financials

Company Details

Developing targeted, immune-mediated oral cancer therapies for broad patient benefit. This clinical-stage biotechnology company focuses on creating small molecule therapeutics to treat cancer. Their approach involves mechanisms that directly target and kill tumor cells while simultaneously activating the body's own tumor-specific immunity. The company is developing first-in-class oral drug therapeutics with the potential to offer significant advantages to a wide range of cancer patients. They explore both new and validated pathways to discover and develop novel therapeutics. Their pipeline represents innovative approaches to cancer treatment, aiming to improve patient outcomes through targeted and immune-mediated strategies. The company's focus is on oncology drug discovery and development, with the goal of advancing novel therapeutics that will bring meaningful benefit to patients.

Website: www.tempesttx.com/
Email ID: *****@tempesttx.com

Key Metrics

Founded Year

2011

Location

San Francisco, United States

Stage

Public

Total Funding

$88.2M in 5 rounds

Latest Funding Round

Post IPO, Mar 23, 2026, $*****

Investors

Versant Ventures & 7 more

Ranked

170^th among 3220 active competitors

Employee Count

14 as on Apr 30, 2026

Similar Companies

Jazz Pharmaceuticals & 2986 more

Exit Details

Public

View TEMPEST THERAPEUTICS's full profile

TEMPEST THERAPEUTICS is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Tempest Therapeutics, Inc. CIN: 45-1472564 , United States, Active	Apr 04, 2011	-	19 (As on Dec 31, 2022)	-

TEMPEST THERAPEUTICS got listed on Jun 16, 2021.

Click here to take a look at TEMPEST THERAPEUTICS's IPO in detail

TEMPEST THERAPEUTICS has raised a total funding of $88.2M over 5 rounds. Its first funding round was on Nov 23, 2011. TEMPEST THERAPEUTICS has 8 institutional investors.

Here is the list of recent funding rounds of TEMPEST THERAPEUTICS:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 23, 2026	7667329	Post IPO	6102844	7740206	3847137	1039945
Mar 20, 2026	3681565	Post IPO	1722945	7228179	6362211	9865397
Feb 11, 2020	6367647	Series B	5614461	6339929	F-Prime Capital & 2 more	Lilly Asia Ventures & 2 more

Access funding benchmarks and valuations. Sign up today!

View details of TEMPEST THERAPEUTICS's funding rounds and investors

TEMPEST THERAPEUTICS's employee count trend

TEMPEST THERAPEUTICS has 14 employees as of Apr 26. Here is TEMPEST THERAPEUTICS's employee count trend over the years:

Employee count trend for TEMPEST THERAPEUTICS

Uncover TEMPEST THERAPEUTICS's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of TEMPEST THERAPEUTICS include Jazz Pharmaceuticals, Moderna and Sana Biotechnology. Here is the list of Top 10 competitors of TEMPEST THERAPEUTICS, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, Astrazeneca & 31 others	80/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Bezos Expeditions, F-Prime Capital & 17 others	75/100
4th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	74/100
5th	Juno Therapeutics 2013, Seattle (United States), Acquired	Global biopharmaceutical company discovering, developing, and delivering innovative medicines	$317M	BB Biotech, RA Capital Management & 14 others	74/100
6th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Third Rock Ventures, Nextech Invest & 20 others	73/100
7th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
8th	Regeneron Pharmaceuticals 1988, Tarrytown (United States), Public	Developer of antibodies for the treatment of cancer, eye diseases, inflammatory diseases & others	-	BB Biotech, Kaccelerator & 7 others	72/100
9th	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	72/100
10th	MacroGenics 2000, Rockville (United States), Public	Developer of novel biologics for the treatment of autoimmune disorders, cancer and infectious disease	$126M	Nextech Venture, Ventures West & 29 others	72/100
170th	TEMPEST THERAPEUTICS 2011, San Francisco (United States), Public	Developing targeted, immune-mediated oral cancer therapies for broad patient benefit	$88.2M	F-Prime Capital, Foresite Capital & 6 others	59/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on TEMPEST THERAPEUTICS's competitors? Click here to see the top ones

TEMPEST THERAPEUTICS has made no investments or acquisitions yet.

Here is the latest report on TEMPEST THERAPEUTICS's sector:

Free

Oncology - Sector Report

Edition: October, 2025 (81 Pages)

View all reports related to TEMPEST THERAPEUTICS

Media has covered TEMPEST THERAPEUTICS for a total of 19 events in the last 1 year, 4 of them have been about company updates and 1 about partnerships.